StreetInsider.com News Articles

Form 8-K Vir Biotechnology, Inc. For: Oct 09

Wed, 14 Oct 2026 08:35:00 -0400

si-local-file:///var/storage/secattach/20261014/27184369.html

Vir Biotechnology and Gilead Sciences strike solid tumor drug deal

Wed, 14 Oct 2026 08:30:25 -0400

Vir Biotechnology, Inc. (Nasdaq: VIR) announced a collaboration and license agreement with Gilead Sciences to discover and develop three novel dual-masked T-cell engager (TCE) candidates targeting solid tumor-associated antigens, according to a company press release.

Under the terms of the agreement, Vir Biotechnology will lead discovery, design and optimization of the three TCE candidates using its proprietary platforms, including its PRO-XTEN® masking technology and dAIsY™ protein engineering platform. Gilead will receive an exclusive license to nominate, develop, manufacture and commercialize the resulting candidates.

Vir Biotechnology is eligible to receive up to $135 million in upfront and near-term preclinical milestone payments. This consists

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

Wed, 14 Oct 2026 08:30:00 -0400

- Collaboration combines Vir Biotechnology’s T-cell engager discovery, AI-enabled protein engineering and clinically-validated PRO-XTEN® masking technology with Gilead’s oncology development and commercialization expertise

- This is the Company’s second collaboration building on the universal PRO-XTEN® masking technology

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today announced a collaboration and license agreement with Gilead to discover and engineer three novel PRO-XTEN® dual-masked T-cell engager (TCE) development candidates targeting selected solid tumor-associated antigens. Gilead will have an exclusive license to develop and commercialize the novel TCEs.

Through this collaboration, Vir Biotechnology will apply its deep expertise in TCE discovery and protein

Vir Biotechnology Enters Multi-Program Collaboration and License Agreement with Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors

Wed, 14 Oct 2026 08:30:00 -0400

- This is the Company’s second collaboration building on the universal PRO-XTEN® masking technology

Through this collaboration, Vir Biotechnology will apply its deep expertise in TCE discovery and protein

Form 8-K Vir Biotechnology, Inc. For: Oct 08

Thu, 08 Oct 2026 08:39:00 -0400

si-local-file:///var/storage/secattach/20261008/27164434.html

FDA grants fast track status to Vir Biotechnology's prostate cancer drug

Thu, 08 Oct 2026 08:30:56 -0400

Vir Biotechnology, Inc. (Nasdaq: VIR) announced that the U.S. Food and Drug Administration granted Fast Track designation to VIR-5500, a PSMA-targeted dual-masked T-cell engager, for the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC).

VIR-5500 is being co-developed by Vir Biotechnology and Astellas Pharma Inc. through a global strategic collaboration. The FDA's Fast Track designation is intended to facilitate and expedite the development and review of drugs that treat serious conditions and fill an unmet medical need.

The drug is currently being evaluated in a Phase 1 study across six dose-expansion cohorts. Monotherapy cohorts include patients with taxane naïve mCRPC, radioligand therapy

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

Thu, 08 Oct 2026 08:30:00 -0400

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to VIR-5500, a PSMA-targeted PRO-XTEN® dual-masked T-cell engager (TCE), for the treatment of late-line metastatic castration-resistant prostate cancer (mCRPC). VIR-5500 is being co-developed by Astellas Pharma Inc. and Vir Biotechnology through a global strategic collaboration.

“Receiving Fast Track designation reflects the potential of VIR-5500 to address an area of serious unmet need in late-line mCRPC and the strong momentum we have achieved with Astellas as we prepare to enter pivotal Phase 3 development in 2027,” said

Vir Biotechnology Announces PSMA-targeted PRO-XTEN® Dual-masked T-cell Engager VIR-5500 Received FDA Fast Track Designation for the Treatment of Prostate Cancer

Thu, 08 Oct 2026 08:30:00 -0400

Vir Biotechnology (VIR) PT Raised to $22 at H.C. Wainwright

Thu, 08 Oct 2026 07:09:43 -0400

(Updated - October 8, 2026 7:09 AM EDT)

H.C. Wainwright analyst Patrick Trucchio raised the price target on Vir Biotechnology (NASDAQ: VIR) to $22.00 (from $20.00) while maintaining a Buy rating.

The analyst commented: "We are raising our price target on Vir to $22 from $20, driven by our increased confidence in the dual-masking T cell engager (TCE) PRO-XTEN oncology platform, and positive read-across from third-party pivotal stage de-risking of the hepatitis delta virus (HDV) landscape. In this report, we provide a deep dive analysis into Vir's two franchises: 1) HDV, which is approaching an inflection with topline data from the Phase

Vir Biotechnology (VIR) PT Raised to $22 at H.C. Wainwright

Thu, 08 Oct 2026 07:09:43 -0400

(Updated - October 8, 2026 7:09 AM EDT)

H.C. Wainwright analyst Patrick Trucchio raised the price target on Vir Biotechnology (NASDAQ: VIR) to $22.00 (from $20.00) while maintaining a Buy rating.

Vir Biotechnology names David Liu as chief medical officer

Wed, 07 Oct 2026 08:30:27 -0400

Vir Biotechnology, Inc. (Nasdaq: VIR) announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 12, 2026, according to a company statement.

Liu will oversee clinical development, medical affairs, and regulatory affairs at the San Francisco-based clinical-stage biopharmaceutical company.

Liu joins Vir Biotechnology from Nuvation Bio, where he served as Chief Medical Officer. Before that, he held the same role at 3D Medicines. Earlier in his career, he served as Executive Medical Director at Celgene Corporation and held leadership positions at Bristol Myers Squibb and AstraZeneca.

Liu holds an M.D. from Beijing Medical University, an

Vir Biotechnology Appoints David Liu as Chief Medical Officer

Wed, 07 Oct 2026 08:30:00 -0400

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of David Liu, M.D., Ph.D., as Executive Vice President and Chief Medical Officer (CMO), effective October 12, 2026. Dr. Liu will be responsible for leading the clinical development, medical affairs and regulatory affairs functions.

“David brings extensive immuno-oncology leadership experience, a strong track record of advancing and securing approvals for innovative cancer therapies and deep expertise in global regulatory strategy and execution,” said Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology. “I look forward to partnering with him as we advance our

Vir Biotechnology Appoints David Liu as Chief Medical Officer

Wed, 07 Oct 2026 08:30:00 -0400

Form 3 Vir Biotechnology, Inc. For: Oct 05 Filed by: Sawaf Aziz

Tue, 06 Oct 2026 14:14:00 -0400

si-local-file:///var/storage/secattach/20261006/27154810.html

Vir Biotechnology to present hepatitis delta trial data at AASLD 2026

Mon, 05 Oct 2026 16:05:21 -0400

Vir Biotechnology, Inc. (Nasdaq: VIR) announced it will present Phase 2 SOLSTICE trial data on the combination of elebsiran and tobevibart for chronic hepatitis delta at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2026 in Denver, Colorado, running November 5–9, 2026.

Two oral presentations are scheduled for November 8. The first, presented by Tarik Asselah at 2:15 p.m. MT, will cover HDV RNA response patterns through Week 96 in participants with chronic hepatitis delta. The second, presented by Upkar Gill at 6:00 p.m. MT, will address intrahepatic natural killer cell changes observed with the drug

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026

Mon, 05 Oct 2026 16:05:00 -0400

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will present data from the Phase 2 SOLSTICE trial evaluating the combination of elebsiran and tobevibart for chronic hepatitis delta at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026 in Denver, CO, November 5-9, 2026.

Efficacy of elebsiran (VIR-2218) and tobevibart (VIR-3434) in participants with chronic hepatitis delta infection: Patterns of HDV RNA responses through Week 96
Format: Oral presentation
Session: Hepatitis – Other Infections
Presenter: Tarik Asselah
Date: November 8, 2026
Time: 2:15 p.m. to 2:30 p.m.

Vir Biotechnology to Present Expanded Phase 2 SOLSTICE Results for Elebsiran and Tobevibart in Hepatitis Delta at AASLD’s The Liver Meeting® 2026

Mon, 05 Oct 2026 16:05:00 -0400

Efficacy of elebsiran (VIR-2218) and tobevibart (VIR-3434) in participants with chronic hepatitis delta infection: Patterns of HDV RNA responses through Week 96
Format: Oral presentation
Session: Hepatitis – Other Infections
Presenter: Tarik Asselah
Date: November 8, 2026
Time: 2:15 p.m. to 2:30 p.m.

Form 8-K Vir Biotechnology, Inc. For: Oct 01

Thu, 01 Oct 2026 08:34:00 -0400

si-local-file:///var/storage/secattach/20261001/27132192.html

Vir Biotechnology names Aziz Sawaf as CFO, effective Oct. 2026

Thu, 01 Oct 2026 08:30:55 -0400

Vir Biotechnology, Inc. (Nasdaq: VIR) has appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026, according to a company statement.

Sawaf will oversee the company's finance, IT, and investor relations functions. He joins from Theravance Biopharma, Inc., where he served as CFO since 2023 and as Senior Vice President of Operations Strategy since 2025. Before that, he held financial leadership roles of increasing responsibility at Theravance after joining in 2014, and prior to that worked on R&D and commercial finance teams at Gilead Sciences.

Sawaf holds a B.S. in Business Administration from the University of Arizona,

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

Thu, 01 Oct 2026 08:30:00 -0400

SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the appointment of Aziz Sawaf, MBEE, MBA, CFA, as Executive Vice President and Chief Financial Officer (CFO), effective October 5, 2026. Mr. Sawaf will be responsible for leading the finance, IT and investor relations functions.

“I am delighted to welcome Aziz to the executive leadership team. His experience in driving financial performance across the biotech lifecycle, from clinical development through regulatory approval and commercialization, will be a valuable asset for Vir Biotechnology’s next phase of growth,” said Marianne De Backer, President and Chief Executive Officer of Vir Biotechnology.

Vir Biotechnology Appoints Aziz Sawaf as Chief Financial Officer

Thu, 01 Oct 2026 08:30:00 -0400

Raymond James Reiterates Strong Buy Rating on Vir Biotechnology (VIR)

Mon, 28 Sep 2026 14:03:29 -0400

Raymond James analyst Sean McCutcheon reiterated a Strong Buy rating and $19.00 price target on Vir Biotechnology (NASDAQ: VIR).

The analyst comments "On Monday, before market open, Mirum (MIRM, covered by Ryan Deschner - see his note) announced that the Phase 3 portion of the AZURE-1 study, testing brelovitug in chronic hepatitis delta virus infection (cHDV) met its primary endpoint, and disclosed key secondary endpoints across QW and Q4W dosing schedules. Overall the results are as expected, and we see no impact on the probability of success for Vir’s slate of cHDV pivotal studies to readout starting 4Q26. On net, we

Form 144 Vir Biotechnology, Inc. Filed by: O'Byrne Jason

Thu, 17 Sep 2026 10:15:00 -0400

si-local-file:///var/storage/secattach/20260917/27074153.html

Form 144 Vir Biotechnology, Inc. Filed by: O'Byrne Jason

Tue, 25 Aug 2026 11:07:00 -0400

si-local-file:///var/storage/secattach/20260825/26972824.html

Form 144 Vir Biotechnology, Inc. Filed by: O'Byrne Jason

Tue, 25 Aug 2026 11:07:00 -0400

si-local-file:///var/storage/secattach/20260825/26972824.html